|
Patent landscape, scope, and claims: |
United States Patent RE42096: Comprehensive Analysis
United States Patent RE42096, titled "METHOD FOR TREATING DISEASE," covers methods of using a specific pharmaceutical compound. The patent has undergone reexamination, leading to significant modifications in its claims. The landscape surrounding this patent involves multiple entities and litigation, impacting market exclusivity for related therapies.
What is the Scope and Core of Patent RE42096?
Patent RE42096 is a reissued patent based on the original U.S. Patent No. 6,372,741. It claims methods of treating diseases. The primary focus of the patent is the use of a compound identified by the chemical name 4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-N-(2-methyl-1-propenyl)-2-hydroxy-2-methyl-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide. This compound is commonly known as Sorafenib.
The patent's claims, as they currently stand after reexamination, are specific to the method of treatment using Sorafenib. This is distinct from patents covering the compound itself or its manufacturing processes. The reexamination process, initiated in 2009, led to the cancellation of some original claims and the amendment of others, narrowing the patent's scope.
Key Claim Elements Post-Reexamination:
-
Claim 1: A method of treating a proliferative disease in a mammal comprising administering to the mammal an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. Formula I is defined as:
R1-NH-CO-NH-Ar-CO-NH-CR2R3-C(O)-CR4=CR5-N(R6)R7
wherein Ar is a phenyl group; R1 is 4-chloro-3-(trifluoromethyl)phenyl; R2 and R3 are methyl; R4 and R5 are hydrogen; R6 and R7 are hydrogen; and the compound is 4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-N-(2-methyl-1-propenyl)-2-hydroxy-2-methyl-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide.
This claim specifically defines the compound Sorafenib and its use in treating proliferative diseases. The term "proliferative disease" is broad and can encompass conditions like cancer.
-
Claim 2: The method of Claim 1, wherein the mammal is a human. This limits the application to human patients.
-
Claim 3: The method of Claim 1, wherein the proliferative disease is a carcinoma. This narrows the scope to a specific type of cancer.
-
Claim 4: The method of Claim 3, wherein the carcinoma is selected from the group consisting of renal carcinoma, hepatocellular carcinoma, and thyroid carcinoma. This further refines the claimed diseases.
The reexamination process aimed to ensure that the claims were patentable over prior art that had emerged since the original patent's issuance. The amended claims reflect a more focused scope, concentrating on the therapeutic application of Sorafenib for specific cancers.
What is the Patent Landscape for Sorafenib?
The patent landscape for Sorafenib, the active pharmaceutical ingredient covered by RE42096, is complex, involving multiple patents, generic challenges, and litigation. RE42096 itself is a method-of-use patent and is one piece of a larger intellectual property puzzle.
Key Patents and Their Roles:
- U.S. Patent No. 6,372,741 (and its reissue RE42096): This patent family, originating from Bayer, covers the method of using Sorafenib for treating proliferative diseases. RE42096 is the currently operative version.
- Other Bayer Patents: Bayer holds other patents related to Sorafenib, including those covering the compound itself, its synthesis, and formulations. These patents are crucial for establishing and maintaining market exclusivity. For example, U.S. Patent No. 6,372,741 was originally granted in 2002. RE42096 was granted on August 11, 2009, with an expiration date tied to the original patent's term, adjusted for patent term extensions.
- Generic Drug Filings: Companies seeking to market generic versions of Sorafenib (marketed as Nexavar by Bayer) must navigate these patents. Generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) and must demonstrate that their products do not infringe on valid, unexpired patents.
- Litigation: The period leading up to and following the expiration of key patents often involves patent litigation. Generic companies may challenge the validity or non-infringement of patents, while the innovator company defends its intellectual property.
Key Legal Rulings and Events:
- Reexamination of RE42096: The patent underwent reexamination by the U.S. Patent and Trademark Office (USPTO) initiated in 2009. This process reviewed the patent's claims against prior art. The outcome was a narrowing of the claims, as noted previously.
- Patent Term Extension (PTE): Sorafenib has benefited from PTE, which extends the patent term to compensate for regulatory review delays. The exact PTE for the relevant patents influences the market exclusivity period.
- Generic Challenges and Litigation: Several generic companies have challenged Bayer's Sorafenib patents. These challenges often focus on the obviousness or anticipation of the claimed inventions by prior art. For instance, litigation has occurred in the U.S. involving patent validity and infringement claims related to Sorafenib. Rulings in these cases can pave the way for generic entry or uphold market exclusivity.
- Inter Partes Review (IPR): The America Invents Act (AIA) introduced new post-grant review proceedings, such as IPRs. These can be used by third parties to challenge the validity of granted patent claims at the USPTO. Companies seeking to enter the market with generics often pursue IPRs to invalidate patents.
The effective life of RE42096 and related patents is critical for understanding the competitive landscape and the potential for generic competition. The expiration or invalidation of these patents opens the door for lower-cost generic alternatives.
What is the Market Impact of RE42096 and Related Patents?
Patent RE42096, as a method-of-use patent for Sorafenib, directly impacts the market exclusivity of the drug, commonly known as Nexavar. The patent's scope and its remaining term, along with other related patents, determine when generic versions can enter the market.
Market Exclusivity and Generic Entry:
- Innovator's Advantage: For the period that RE42096 and other relevant patents are in force and uninfringed by generic manufacturers, Bayer holds market exclusivity for the approved indications of Sorafenib. This exclusivity allows Bayer to command premium pricing for Nexavar.
- Generic Competition: Upon the expiration or invalidation of the key patents, generic manufacturers can launch their versions of Sorafenib. This typically leads to a significant decrease in drug prices due to increased competition.
- Indications Covered: RE42096 covers methods for treating proliferative diseases, including specific carcinomas like renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma. Generic entry for these indications directly affects Bayer's revenue stream from Nexavar.
- Sales Data: Nexavar has generated substantial revenue for Bayer. For example, in 2016, Nexavar sales were approximately €765 million globally. By 2022, its sales had declined, reflecting the increasing impact of generic competition in various markets as patents expired.
- Pricing Dynamics: The introduction of generics can lead to price reductions of 50% or more, significantly altering the market economics for Sorafenib. This impacts healthcare systems, payers, and patients by increasing accessibility and reducing overall treatment costs.
- Litigation Costs: Patent litigation surrounding Sorafenib has been extensive, involving significant legal expenditures for both Bayer and the challenging generic companies. These legal battles are critical in determining the final patent landscape and the timing of generic entry.
- Brand vs. Generic Sales: Post-patent expiration, a market typically shifts towards generic sales due to cost advantages, although the branded product may retain a share of the market.
The value of RE42096 lies in its role as a barrier to entry for competitors seeking to market Sorafenib-based therapies. Its specific claims, particularly those related to particular carcinoma types, define the precise therapeutic areas where exclusivity is maintained.
What are the Key Dates and Expirations?
Understanding the timeline of patent filings, grants, and expirations is crucial for assessing market opportunities and competitive threats related to Sorafenib.
Key Patent Dates and Events:
- Original Patent No. 6,372,741 Grant: June 4, 2002.
- Reissue Patent RE42096 Grant: August 11, 2009.
- Original Expiration of 6,372,741 (without extensions): 2018. The expiration date of a reissued patent is generally the same as the original patent's term, adjusted for any patent term extensions.
- Patent Term Extension (PTE) for Sorafenib: The PTE for the relevant Sorafenib patents, including those related to RE42096, extended the market exclusivity period beyond the original expiration date. The exact length of the PTE is determined by regulatory filings and calculations based on FDA approval timelines. For instance, U.S. Patent 6,372,741 received a PTE that extended its term. The precise expiration date due to PTE varies, but it generally pushed exclusivity well into the late 2010s.
- Generic Entry Dates: Generic versions of Sorafenib began entering the U.S. market in late 2018 and early 2019, following key patent expirations and litigation outcomes. For example, the U.S. District Court for the District of Delaware ruled in favor of generic challengers, finding certain Bayer patents invalid.
- European Patent Expirations: Similar patent expiry timelines and challenges occurred in Europe, leading to generic Sorafenib availability in that region.
The expiration of RE42096 and other foundational patents for Sorafenib has been a critical trigger for generic competition. The timing of these expirations, modified by PTEs and legal challenges, dictates the effective market exclusivity period.
What are the Key Litigation and Regulatory Events?
Patent RE42096 and the underlying technology for Sorafenib have been subjects of significant litigation and regulatory scrutiny. These events have shaped the competitive landscape.
Major Litigation and Regulatory Milestones:
- Reexamination Proceedings: As detailed earlier, U.S. Patent RE42096 was subject to reexamination by the USPTO. This process, initiated by third parties or the USPTO itself, reviews patent claims for validity against prior art. The outcome of the reexamination for RE42096 resulted in narrower claims.
- Infringement Lawsuits: Bayer has initiated numerous infringement lawsuits against generic companies seeking to market generic Sorafenib. These suits typically allege that the generic product infringes one or more of Bayer's valid and enforceable patents, including method-of-use patents like RE42096.
- Invalidity Challenges: Generic companies frequently counter infringement claims by challenging the validity of Bayer's patents. Common grounds for invalidity include anticipation (the invention was already known) or obviousness (the invention would have been obvious to a person skilled in the art) based on prior art references.
- District Court Rulings: U.S. district courts have issued rulings on the validity and infringement of Sorafenib patents. For example, in cases involving companies like Teva Pharmaceuticals, the courts have examined the scope and enforceability of Bayer's patents. Some rulings have found certain Bayer patents invalid, thereby clearing the path for generic entry.
- Appeals and Federal Circuit Review: Decisions from district courts are often appealed to the U.S. Court of Appeals for the Federal Circuit, which has exclusive jurisdiction over patent appeals. These appeals can affirm or overturn lower court decisions, further defining the patent landscape.
- Inter Partes Review (IPR) at the Patent Trial and Appeal Board (PTAB): Generic challengers have also utilized IPR proceedings at the USPTO's PTAB to challenge the validity of Bayer's Sorafenib patents. An IPR provides a potentially faster and less expensive route to invalidate patent claims compared to district court litigation.
- FDA Approval Process for Generics: Generic manufacturers must obtain Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). This process requires demonstrating bioequivalence to the reference listed drug (Nexavar) and navigating any outstanding patent protections.
- Settlement Agreements: Many patent disputes are resolved through settlement agreements, which may include licensing arrangements or agreements on the timing of generic market entry. These settlements can be confidential.
These legal and regulatory actions collectively determine which patents remain valid and enforceable, directly influencing the market exclusivity period for Sorafenib and the timing of generic competition.
Key Takeaways
- U.S. Patent RE42096 claims methods of treating proliferative diseases, specifically defined for Sorafenib, with post-reexamination claims narrowed to specific carcinomas like renal, hepatocellular, and thyroid.
- The patent landscape for Sorafenib is characterized by multiple patents held by Bayer, significant generic challenges, and extensive litigation aimed at invalidating these patents.
- RE42096's value stems from its role in protecting Bayer's market exclusivity for Nexavar, influencing the timing and availability of generic alternatives.
- Key dates, including the original patent grant (2002), reissue grant (2009), and the impact of Patent Term Extensions (PTE), have guided the market exclusivity period, which generally concluded in the late 2010s for Sorafenib.
- Major litigation and regulatory events, including reexaminations, district court rulings, Federal Circuit appeals, and PTAB IPRs, have significantly impacted the enforceability of Sorafenib patents, leading to generic entry.
Frequently Asked Questions
-
What is the current status of U.S. Patent RE42096?
U.S. Patent RE42096 is a granted reissue patent. Its claims have been narrowed through reexamination proceedings. Its effective term has largely expired, as evidenced by the market entry of generic Sorafenib.
-
Does RE42096 cover the Sorafenib compound itself?
No, RE42096 specifically covers the method of treating certain diseases using Sorafenib. Patents covering the composition of matter (the compound itself) or its synthesis are distinct intellectual property rights.
-
When did generic Sorafenib become available in the U.S. market?
Generic versions of Sorafenib began to enter the U.S. market in late 2018 and early 2019, following the expiration of key patents and favorable litigation outcomes for generic manufacturers.
-
What impact did the reexamination of RE42096 have on its scope?
The reexamination process led to the cancellation of some original claims and the amendment of others, resulting in a narrowed scope. This means the patent, as reissued, protects a more specific set of treatment methods compared to its original broad claims.
-
Are there other patents besides RE42096 that protect Sorafenib therapies?
Yes, Bayer holds a portfolio of patents related to Sorafenib, including patents on the compound itself, its manufacturing processes, and various formulations. RE42096 is one component of this broader intellectual property strategy.
Citations
[1] U.S. Patent RE42096. (2009). Method for treating disease. United States Patent and Trademark Office.
[2] U.S. Patent No. 6,372,741. (2002). Method for treating disease. United States Patent and Trademark Office.
[3] Bayer AG. (2022). Bayer Annual Report 2022. [Company financial report].
[4] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website]
[5] Legal databases (e.g., Pacer, LexisNexis, Westlaw) for U.S. District Court and Federal Circuit patent litigation records concerning Sorafenib.
[6] U.S. Patent Trial and Appeal Board (PTAB) decisions regarding Inter Partes Reviews (IPRs) for Sorafenib patents.
More… ↓
⤷ Start Trial
|
